Disc Medicine (IRON) COO Jonathan Yen-Wen Exercises Options, Sells Shares

What Happened

• Jonathan Yen-Wen, Chief Operating Officer of Disc Medicine (IRON), exercised stock options and sold the resulting shares in open-market transactions. On Aug 24–25, 2026 he exercised a total of 9,096 shares (300 + 8,796) at an exercise price of $13.50 per share (total exercise cost $122,796) and sold those shares for aggregate proceeds of about $755,852. The filing shows additional derivative "disposed" entries at $0.00 per share associated with those exercises.
• These transactions are sales (routine monetization after option exercises) rather than purchases and were effected pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction dates and prices:
  • 2026-08-24: Exercised 300 shares at $13.50 (cost $4,050); sold 300 shares at a weighted avg $82.53 (range $82.50–$82.60) — proceeds ~$24,760.
  • 2026-08-25: Exercised 8,796 shares at $13.50 (cost $118,746); sold 8,796 shares at a weighted avg $83.12 (range $82.57–$83.47) — proceeds ~$731,092.
• Aggregate: exercised 9,096 shares (exercise cost $122,796) and sold 9,096 shares for total proceeds of ~$755,852 (net proceeds before taxes/withholdings ≈ $633,056).
• Shares owned after the transactions: not specified in the Form 4 filing.
• Notable footnotes:
  • F1: Transactions were made under a Rule 10b5-1 trading plan adopted March 17, 2026.
  • F2/F3: Sale prices are weighted averages; shares were sold in multiple trades within the stated price ranges.
  • F4: The underlying options vest monthly over 48 months beginning Dec 29, 2022.
• Filing timeliness: Reported on Aug 26, 2026 for transactions on Aug 24–25 — appears timely (filed within required Form 4 reporting window).

Context

• For retail investors: this was an option exercise followed by immediate open-market sales — effectively converting vested option shares to cash under a pre-planned 10b5-1 program. The filing is factual and does not indicate the insider’s motivations.